Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Awards
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
    • Women in Healthcare
    • - Luminaries
    • - Top 25 Diversity Leaders
    • - Leaders to Watch
    • - Luminaries
    • - Top 25 Women Leaders
    • - Women to Watch
  • Events
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Custom Media Event: ESG Summit
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Social Determinants of Health Symposium
    • Leadership Symposium
    • Health Care Hall of Fame Gala
    • Top 25 Women Leaders Gala
    • Best Places to Work Awards Gala
    • Top 25 Diversity Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Strategic Marketing
    • - Virtual Health
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Finance
January 15, 2015 12:00 AM

Gout-drug competition returning to market after court fight

Jaimy Lee
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    A drug that's been on the market for decades and is commonly used to treat gout may once again return to the U.S. market with a cheaper price.

    The U.S. Court of Appeals for the Federal Circuit issued an order Jan. 9 that essentially allows West-Ward Pharmaceuticals Corp., an Eatontown, N.J.-based generic-drug manufacturer, to begin selling a new version of colchicine.

    Takeda Pharmaceuticals USA, which makes the brand-name version of the drug and brought the lawsuit against West-Ward, also announced plans this week to partner with a separate manufacturer to bring generic versions of the treatment to market.

    Allowing generic manufacturers to market the drug is expected to lower the costs of a therapy that only a decade ago cost 10 cents per pill and now costs more than $5 per pill.

    The American College of Rheumatology, which filed a brief in support of West-Ward, applauded the news. A spokeswoman said the organization expects the price of the drug to drop although pricing details were not immediately available.

    “The ACR is pleased that it was able to play an important role in the reintroduction of competition to the colchicine market, which will drive down the cost of colchicine prophylaxis therapy for rheumatology patients nationwide,” the organization said.

    Colchicine has been used by the medical community for decades to treat people with gout as well as patients with familial Mediterranean fever. It was allowed to be sold without approval from the Food and Drug Administration because it had been on the market before the current approval process existed. An estimated 2% of drugs available in the U.S. in 2006 were unapproved.

    Safety concerns about these drugs led to the creation in 2006 of an FDA program that encouraged manufacturers to gain regulatory approval of unapproved therapies. Unapproved colchicine was associated with at least 117 non-overdose deaths, half of which were due to drug interactions, Kalah Auchincloss, acting director of the FDA's Office of Unapproved Drugs and Labeling Compliance, told Modern Healthcare last year.

    URL Pharma, a company later acquired by Takeda, received FDA approval in 2009 for branded colchicine, naming it Colcrys. The FDA's later enforcement action against companies marketing unapproved versions of the drug and the exclusivity granted to the company for the two indications eventually meant that Colcrys was the only available version of colchicine on the market.

    While clinical trials yield new data about the drug's dosing and efficacy, going through the approval process led the company to increase the cost of the drug. Colchicine's rise from 10 cents to $5 a pill troubled consumers who saw the price of their prescriptions rapidly increase.

    It appears there will now be three manufacturers of the drug—Takeda; Prasco Laboratories, in a generic partnership with Takeda; and West-Ward—as a result of the order blocking Takeda's motion for preliminary injunction against West-Ward.

    “This new partnership will help enhance patient access to an important gout medicine by supplying Prasco with colchicine tablets manufactured under the same rigorous standards and processes as Colcrys,” said Douglas Cole, president of Takeda Pharmaceuticals USA.

    Takeda will continue making the brand-name version of the drug, as well.

    Follow Jaimy Lee on Twitter: @MHjlee

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Copy of transparencyhospital costs_0001_i copy_i.png
    Fines kicking in after slow start to hospital transparency rule
    vaccine-money_i.png
    U.S. diverts COVID-19 funds to secure vaccines amid stalemate
    Sponsored Content
    Daily Finance Newsletter: Sign up to receive daily news and data that has a direct impact on the business and financing of healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Nominate/Eligibility
      • 100 Most Influential People
      • 50 Most Influential Clinical Executives
      • Best Places to Work in Healthcare
      • Excellence in Governance
      • Health Care Hall of Fame
      • Healthcare Marketing Impact Awards
      • Top 25 Emerging Leaders
      • Top 25 Innovators
      • Diversity in Healthcare
        • - Luminaries
        • - Top 25 Diversity Leaders
        • - Leaders to Watch
      • Women in Healthcare
        • - Luminaries
        • - Top 25 Women Leaders
        • - Women to Watch
    • Events
      • Conferences
        • Transformation Summit
        • Women Leaders in Healthcare Conference
        • Social Determinants of Health Symposium
        • Leadership Symposium
      • Galas
        • Health Care Hall of Fame Gala
        • Top 25 Women Leaders Gala
        • Best Places to Work Awards Gala
        • Top 25 Diversity Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Strategic Marketing
        • - Virtual Health
      • Webinars
      • Custom Media Event: ESG Summit
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing